Jacob Plieth — #ASCO26 late-breaker on $IDYA Optimum-02 study is now live: repeats earlier disclosed PFS data, says nothing about OS. Some detail about safety. Presentation in 40 mins.↗
April 2026 · 9 mentions
Apr 30
Jacob Plieth — @ablT315I @adamfeuerstein Can you comment on the #ASCO26 embargo discipline being shown by $IDYA & $KPTI ?↗
Apr 23
Jacob Plieth — Given how much $IDYA has already released (ORR, PFS, stats, PFS curves) I'm a little surprised #ASCO26 is OK with giving it a late-breaker.↗
Apr 13
Jacob Plieth — Optimum-02 virtually replicates Optimum-01, and $IDYA heads for US filing. Via @APEXONCo -> https://t.co/y6X9Hs5kKf↗
Apr 13
Jacob Plieth — @omphalos007 @avidresearch That probably makes an $IMCR vs $IDYA comparison on PFS alone slightly unfair.
October 2025 · 4 mentions
Oct 22
Jacob Plieth — Who won #ESMO25 and who lost? Via @ApexOnco
https://t.co/EWzHIIH1Ck
$IOBT $CELC $RCUS $CGEM $IDYA $NUVL $AGEN $GILD $DSNKY $INCY $CATX $LPTX $OLMA $SMMT $AVBP $GMAB $EXEL $CGEN $Z…↗
Oct 18
Jacob Plieth — Novel synthetic lethality approaches from Synnovation, Artios & $NVS leave much to prove. Via @ApexOnco at #ESMO25 -> https://t.co/B5FWHlomX6 $IDYA $RPTX $GSK↗
Oct 13
Jacob Plieth — @jeromeleonard5 @NotthatkindofDr At #Jefferies24 $IDYA said data were expected at a medical conf in 2025, if I recall.↗
Oct 13
Jacob Plieth — @jeromeleonard5 @NotthatkindofDr GSK4418959 / IDE275? I was kind of hoping to see FIH data on that at #ESMO25 $GSK $IDYA
September 2025 · 1 mention
Sep 8
Jacob Plieth — If you're catching up with #WCLC25 news, @ApexOnco coverage can be found here: https://t.co/Jl2xGAtcZw $SMMY $IDYA $AZN $JNJ $BMY $ZLAB $BNTX↗
Jacob Plieth — @avidresearch Kimmtrak is weird - nice OS benefit, hardly anything on PFS. I can't recall why at this point $IMCR $IDYA↗
Apr 13
Jacob Plieth — $IDYA PFS curves from Optimum-02 https://t.co/h4ZYytTrsc↗
Apr 13
Jacob Plieth — Let's remember again that $NVS dumped off darovasertib for $2.5m in cash + $3.5m in $IDYA series B preferred stock.↗
Apr 13
Jacob Plieth — $IDYA darovasertib data from registrational Optimum-02 trial in uveal melanoma are out. What to look for: https://t.co/1LQa0X6xJa↗
Apr 10
Jacob Plieth — This is getting quite tiresome: first $ORIC, now $ALLO & $IDYA. Why are you sitting on market-sensitive data rather than releasing it now? https://t.co/N8q95re7ho↗